News Outlets Report On Various Aspects Of COVID-19 Treatment, Vaccine R&D
AP: Vaccine storage issues could leave 3B people without access (Hinnant/Mednick, 10/25).
AP: Brazil approves import of Chinese shot that Bolsonaro nixed (Sciaudone, 10/23).
Bloomberg: Venezuela’s Maduro Presents ‘Molecule’ That Inhibits Covid-19 (Zerpa, 10/25).
Bloomberg: Johnson & Johnson, AstraZeneca Trials to Resume, Rejoining Vaccine Race (Griffin et al., 10/24).
DW: Coronavirus: Germany warns against ‘vaccine nationalism’ (Connor, 10/25).
Financial Times: Oxford Covid vaccine trials offer hope for elderly (Neville et al., 10/26).
Financial Times: AstraZeneca and J&J get go-ahead to resume Covid-19 vaccine trials (Kuchler/Stacey, 10/23).
The Guardian: Rush for results could lead to inferior Covid vaccine, say scientists (McKie, 10/25).
New York Times: The Trump Administration Shut a Vaccine Safety Office Last Year. What’s the Plan Now? (Zimmer, 10/23).
Reuters: As it hits 1 million coronavirus cases, Colombia prepares for vaccine (Cobb, 10/24).
Reuters: WHO says it will have advice on Remdesivir in 3-4 weeks (10/23).
Reuters: WHO: Nations mulling Gilead’s COVID drug should consider trial flop, too (Nebehay/Miller, 10/23).
Reuters: Mexico will not follow FDA in approving Gilead’s COVID-19 drug (Angulo/Solomon, 10/23).
STAT: FDA shows signs of cold feet over emergency authorization of Covid-19 vaccines (Branswell, 10/23).
STAT: Why the approval of remdesivir to treat Covid-19 obscures bigger scientific failures (Herper/Feuerstein, 10/23).
Wall Street Journal: To Find a Coronavirus Vaccine, GlaxoSmithKline Is Bonding With Its Biggest Competitors (Walker, 10/24).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.